Tumor News and Research

RSS

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.

2 Nov 2009

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

Bioengineers develop nano-delivery system for cancer therapy

Going smaller could bring better results, especially when it comes to cancer-fighting drugs.

2 Nov 2009

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

According to the American Cancer Society, more than one million people are diagnosed with cancer each year. In the United States, about 1 out of every 2 men and 1 out of every 3 women will have some type of cancer at some point during their lifetime. The sooner a cancer is detected and treatment begins, the better the patient’s chances for survival.

31 Oct 2009

Quintiles and Eisai partner to develop potential oncology products

Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.

31 Oct 2009

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

Hyperthermia therapy delivered through BSD Medical's system improves survival rate for bladder cancer patients

BSD Medical Corporation today announced that published study results demonstrated improvement in overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy, delivered using the BSD-2000 Hyperthermia System, to the standard treatment regimen for 45 patients with high-risk bladder cancer.

30 Oct 2009

Cancer patients in northern Portugal to gain access to advanced cancer treatments

Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR) by the Instituto Portugues Oncologia, IPO Porto.

30 Oct 2009

Helper T cell's effect raises possibility of cellular therapy and vaccine development

A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.

30 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors.

30 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

Researchers use BEZ235 drug to eliminate NSCL cancer

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

New technology enhancements from Varian Medical Systems, designed to make radiotherapy and radiosurgery treatments faster, more accurate, and easier to plan and deliver, will be on display at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago next week.

29 Oct 2009

Tumor News and Research

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Bioengineers develop nano-delivery system for cancer therapy

GE Healthcare to showcase its sophisticated imaging systems for oncology at the ASTRO meeting

Quintiles and Eisai partner to develop potential oncology products

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

Immunotherapy, a new therapeutic area to destroy tumor cells

Hyperthermia therapy delivered through BSD Medical's system improves survival rate for bladder cancer patients

Cancer patients in northern Portugal to gain access to advanced cancer treatments

Helper T cell's effect raises possibility of cellular therapy and vaccine development

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Study: HSP inhibitor could stop tumor formation and extend survival

Fiscal 2009 results announced by Helix BioPharma

Researchers use BEZ235 drug to eliminate NSCL cancer

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News